Project Pipeline -- Mount Milligan's pre-feasibility study (PFS) extends mine life by 10 years to 2045; planned average annual production of 150,000 ounces of gold and 69 million pounds of copper ...

Total production -- Reached a quarterly record of approximately 1.62 million BOEs per day, reflecting a 19% increase, or ...

BradyScan App Launch -- Announced as available on Android and Apple, supporting barcode generation, scanning, security ...

Join us as we dissect Lululemon's stock performance and explore whether it can reclaim its former glory in the competitive ...

Disposition Activity -- Q3 proceeds totaled $19.3 million, with $4.6 million in gains; year-to-date sales reached $133.8 ...

Net Income -- $7.6 million, down from $9.3 million. Net income attributable to Karat ( KRT +1.51%) was $7.3 million, or $0.36 ...

PN-943 (IBD Program) -- Oral, gut-restricted alpha-4-beta-7 integrin antagonist demonstrated greater than threefold improved ...

Relacorilant NDA updates -- FDA PDUFA date set for Dec. 30, 2025 (hypercortisolism); platinum-resistant ovarian cancer PDUFA ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

Both of these electric air taxi pioneers have sold off hard recently, creating a potential entry point for patient investors.

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term ...